Stocks
Merck Stock Hits New High on Raised Guidance Amid Keytruda Competition
Merck & Co.'s stock has reached its recent 52-week high of $150.78 on September 2, 2026, with a market capitalization of $369.73 billion USD.
The company's second-quarter revenue rose 5% year-over-year to $16.61 billion USD, beating the consensus estimate of $16.33 billion USD according to Zacks.
Merck & Co. also raised its full-year sales guidance to between $66.3 billion USD and $67.3 billion USD, representing a 2-4% year-over-year growth rate.
However, the company reduced its adjusted earnings forecast to $2.66-$2.76 per share due to one-time charges related to the acquisition of Terns Pharmaceuticals.